# Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients

> **NCT05817903** · PHASE2 · RECRUITING · sponsor: **Consorzio Oncotech** · enrollment: 118 (estimated)

## Conditions studied

- Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Axitinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT05817903
- **Lead sponsor:** Consorzio Oncotech
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-18
- **Primary completion:** 2026-04-01
- **Final completion:** 2027-04-01
- **Target enrollment:** 118 (ESTIMATED)
- **Last updated:** 2023-05-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05817903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05817903, "Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients". Retrieved via AI Analytics 2026-07-28 from https://api.ai-analytics.org/clinical/NCT05817903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*